CompanyGraph
Duality Biotherapeutics, Inc.
9606 · HKEX · China
Price data from its 4ZB listing on FSX, quoted in EUR
dualitybiologics.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is -$450.53M, lower than 95% of all stocks globally
- PositionReturn on equity is -1282.1%, lower than 95% of its Biotechnology peers (median -23.6%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
30.41BHKD3.88B · vs all stocks (USD)
Revenue (TTM)
2.15BHKD274.67M · vs all stocks (USD)
Profit Margin
-140.13%vs Biotechnology peers
52-Week Change
-43.13%vs all stocks
Market Capitalization
30.41BHKD3.88B · vs all stocks (USD)
Enterprise Value
15.12BHKD1.93B · vs all stocks (USD)
Forward P/E
-24.67xvs Biotechnology peers
Price to Sales (TTM)
9.17xvs Biotechnology peers
Price to Book (MRQ)
5.94xvs Biotechnology peers
Enterprise to Revenue
7.02xvs Biotechnology peers
Enterprise to EBITDA
-28.71xvs Biotechnology peers
Gross Margin
26.11%vs Biotechnology peers
Profit Margin
-140.13%vs Biotechnology peers
Operating Margin
-92.53%vs Biotechnology peers
Return on Assets (TTM)
-9.61%vs Biotechnology peers
Return on Equity (TTM)
-1282.14%vs Biotechnology peers
Revenue (TTM)
2.15BHKD274.67M · vs all stocks (USD)
Revenue per Share (TTM)
28.42HKDUpdated Aug 21, 2026Quarterly Revenue Growth
-33.80%vs Biotechnology peers
Gross Profit (TTM)
685.39MHKD87.38M · vs all stocks (USD)
EBITDA (TTM)
-526.70MHKD-67.15M · vs all stocks (USD)
Net Income (TTM)
-3.02BHKD-384.89M · vs all stocks (USD)
Operating Cash Flow (TTM)
226.39MHKD28.86M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-3.53BHKD-450.53M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
EPS (Basic)
-29.47CNYFY2025 · Dec 31, 2025EPS (Diluted)
-29.47CNYFY2025 · Dec 31, 2025Operating Cash Flow
-2.31BCNYFY2025 · Dec 31, 2025Free Cash Flow
-2.32BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.28BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-2.59BCNYFY2025 · Dec 31, 2025Stock-based Compensation
156.05MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-98.10MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
33.84MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
189.83MCNYFY2025 · Dec 31, 2025Capital Expenditures
-11.50MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-2.22MCNYFY2025 · Dec 31, 2025Purchase of Investments
-4.64BCNYFY2025 · Dec 31, 2025Sale of Investments
2.75BCNYFY2025 · Dec 31, 2025Other Investing Activity
-4.55MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.91BCNYFY2025 · Dec 31, 2025Net Short-term Debt Issuance
141.06MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
1.90BCNYFY2025 · Dec 31, 2025Shares Outstanding
89.42MSharesUpdated Aug 21, 2026Float Shares
50.36MSharesUpdated Aug 21, 2026% Held by Insiders
19.25%vs all stocks
% Held by Institutions
35.60%vs all stocks
Total Cash (MRQ)
3.93BHKD501.39M · vs all stocks (USD)
Total Cash per Share (MRQ)
37.80HKDUpdated Aug 21, 2026Total Debt (MRQ)
174.26MHKD22.22M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0617xvs Biotechnology peers
Current Ratio (MRQ)
3.65xvs Biotechnology peers
Book Value per Share (MRQ)
31.58HKDUpdated Aug 21, 2026Total Assets
3.89BCNY578.91M · vs all stocks (USD)
Total Current Assets
3.83BCNYFY2025 · Dec 31, 2025Total Liabilities
1.47BCNYFY2025 · Dec 31, 2025Total Non-current Assets
58.73MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
414.35MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.05BCNYFY2025 · Dec 31, 2025Cash
3.27BCNYFY2025 · Dec 31, 2025Cash Equivalents
-2.00BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.28BCNYFY2025 · Dec 31, 2025Other Short-term Investments
2.10BCNYFY2025 · Dec 31, 2025Accounts Receivable
277.92MCNYFY2025 · Dec 31, 2025Accounts Payable
761.94MCNYFY2025 · Dec 31, 2025Short-term Debt
145.87MCNYFY2025 · Dec 31, 2025Long-term Debt
3.91MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
169.53MCNYFY2025 · Dec 31, 2025Common Stock (Book)
58.00KCNYFY2025 · Dec 31, 2025Retained Earnings
-4.85BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.43BCNY360.87M · vs all stocks (USD)
52-Week Low
158.50HKDUpdated Aug 21, 202652-Week High
563.50HKDUpdated Aug 21, 202652-Week Change
-43.13%vs all stocks
50-Day MA
199.86HKDUpdated Aug 21, 2026200-Day MA
276.91HKDUpdated Aug 21, 2026Avg 10-Day Volume
1.02MSharesUpdated Aug 21, 2026Avg 30-Day Volume
1.15MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-46.32HKDUpdated Aug 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -1282.1%, lower than 95% of its Biotechnology peers (median -23.6%)Significant
Return on equity: -12.82Industry median: -0.24Industry P5: -1.76Peers compared: 194
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is -$450.53M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -450,528,787.975Global P5: -209,187,555.994
Market cap is $3.88B, above the global median of $1.18BNotable
Market cap (USD): 3,876,680,822.64Global Median: 1,179,398,897.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Huahai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xiamen Amoytop Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Catalyst Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Arcus Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Apeloa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Livzon Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Irhythm Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Denali Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Viking Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationDecline With Range Expansion And Drawdown
Wintao Communications Co.
1 interpretationDecline With Range Expansion And Drawdown
Deltic Energy plc
1 interpretationDecline With Range Expansion And Drawdown